Skip to content

A Hybrid Effectiveness/Implementation Trial of the International Guide for Monitoring Child Development

An Individualized Approach to Promote Nurturing Care in Low and Middle Income Countries: A Hybrid Effectiveness/Implementation Trial of the International Guide for Monitoring Child Development

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04665297
Enrollment
624
Registered
2020-12-11
Start date
2023-01-17
Completion date
2026-04-30
Last updated
2026-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Child Development

Keywords

Guatemala, India, Early Child Development

Brief summary

The aim of this study is to conduct a hybrid effectiveness/implementation assessment of the International Guide for Monitoring Child Development (GMCD) in two LMIC settings, India and Guatemala, within established rural CHW programs. The primary objectives are (a) to evaluate the real-world effectiveness of the GMCD; (b) to use an implementation science framework to understand barriers and facilitators to effective population coverage, provider implementation, and maintenance; (c) to conduct an economic evaluation of the GMCD.

Detailed description

Specific Aim 1: Assess the effectiveness of the GMCD intervention to improve developmental outcomes and nurturing care in India and Guatemala. The investigators will conduct a parallel-arm cluster randomized trial within rural CHW programs. In the primary effectiveness phase, children under 2 years old will receive the GMCD intervention or control for 12 months. Subsequently, control clusters will cross into the intervention, and continue an additional 12 months (total 24 study months). The primary developmental effectiveness outcome will be change in age-adjusted scores at 12 months on the Bayley Scales of Infant Development, 4th Edition BSID4) (3). The secondary nurturing care effectiveness outcome will be change in mean Home Observation for Measurement of the Environment (HOME) score at 12 months (4). Specific Aim 2: Assess barriers and facilitators to GMCD implementation using the RE-AIM evaluation framework (5). RE-AIM domains will be assessed as: (a) Reach: participation rates, comparison of participant/non-participant characteristics, attendance/drop-out; (b) Effectiveness: impact on development (BSID4) and nurturing environment (HOME) \[in Aim 1\]; (c) Adoption: proportion of workers/facilities participating, CHW characteristics; (d) Implementation: contact hours/visit completion, fidelity to delivery protocols; (e) Maintenance: patient outcomes and cost effectiveness analysis at 12-24 months \[in Aim 3\]; intent by decision makers and implementers to continue intervention. In addition, the investigators will conduct a sequential quantitative--\>qualitative explanatory analysis, using interviews and focus groups with implementers from clusters with highest/lowest impact outcomes (BSID4/HOME) to explore institutional inner and outer setting and implementation processes associated with intervention success, using the Consolidated Framework for Implementation Research (CFIR). Specific Aim 3: Conduct an economic evaluation of the GMCD intervention. Evaluation will assess (a) costs of the interventions at 12 and 24 months; and (b) cost-effectiveness of the intervention (dollar per unit increase in BSID or HOME scores) at 12 months. This analysis will provide cost information to policymakers to help guide resource allocation decisions for ECD interventions.

Interventions

BEHAVIORALInternational Guide for Monitoring Child Development

Monthly GMCD visits includes assessment of risk factors, open-ended exploration of caregiver concerns about development, assessment of functioning in seven developmental domains, and using mutual problem solving strategies to develop a nurturing care plan with the caregiver.

Sponsors

Brigham and Women's Hospital
Lead SponsorOTHER
Mahatma Gandhi Institute of Medical Sciences
CollaboratorOTHER
Ummeed Child Development Center
CollaboratorUNKNOWN
Ankara University
CollaboratorOTHER
Wuqu' Kawoq, Maya Health Alliance
CollaboratorOTHER
Harvard Medical School (HMS and HSDM)
CollaboratorOTHER
University of Washington
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Masking description

Given nature of study, blinding is not feasible.

Intervention model description

Nonblinded, two-arm cluster randomized controlled trial for 12 months. At 12 months, control arm crosses into the intervention, and both arms receive the intervention for an additional 12 months (total of 24 months)

Eligibility

Sex/Gender
ALL
Age
0 Months to 24 Months
Healthy volunteers
No

Inclusion criteria

* age 0-24 months at the time of enrollment visit * receiving health services from frontline health workers of Maya Health Alliance (Guatemala), Mahatma Gandhi Institute (India) or their local partners

Exclusion criteria

* children who are critically ill and are judged by the frontline health worker to require hospitalization or center-based care * children whose caregivers do not provide informed consent for the study

Design outcomes

Primary

MeasureTime frameDescription
Change in Composite Language Score at 12 monthsChange from 0 to 12 monthsUsing the Bayley Scales of Infant Development, 4th Edition (BSID4), higher scores better, scale range 47-153
Change in Composite Motor Score at 12 monthsChange from 0 to 12 monthsUsing the Bayley Scales of Infant Development, 4th Edition (BSID4), higher scores better, scale range 46-154
Change in Composite Cognitive Score at 12 monthsChange from 0 to 12 monthsUsing the Bayley Scales of Infant Development, 4th Edition (BSID4), higher scores better, scale range 55-145

Secondary

MeasureTime frameDescription
Change in the Home Observation for Measurement of the Environment Scale (HOME) Raw ScoreChange from 0 to 12 monthsRaw score range 0-45, higher scores better

Countries

Guatemala, India

Contacts

PRINCIPAL_INVESTIGATORPeter Rohloff

Assistant Professor/Associate Physician

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026